DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Shinmura K, Tamaki K, Sato T, et al. Prostacyclin attenuates
oxidative damage of myocytes by opening mitochondrial
ATP-sensitive K+ channels via the EP3 receptor. Am J Physiol
Heart Circ Physiol, 2005, 288:H2093–H2101.
Simon DB, Karet FE, Hamdan JM, et al. Bartter’s syndrome,
hypokalaemic alkalosis with hypercalciuria, is caused by
mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet,
1996, 13:183–188.
Sinal CJ, Miyata M, Tohkin M, et al. Targeted disruption of soluble
epoxide hydrolase reveals a role in blood pressure regulation.
J Biol Chem, 2000, 275:40504–40510.
Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases:
Structural, cellular, and molecular biology. Annu Rev Biochem,
2000, 69:145–182.
Smith WL, Langenbach R. Why there are two cyclooxygenase
isozymes. J Clin Invest, 2001, 107:1491–1495.
Smyth EM, FitzGerald GA. Prostaglandin mediators. In:
Bradshaw RA, Dennis EA, eds. Handbook of Cell Signaling.
Elsevier, 2009.
Smyth EM, Grosser T, Wang M, et al. Prostanoids in health and
disease. J Lipid Res, 2009, 50(suppl):S423–S428.
Stafforini DM. Biology of platelet-activating factor acetylhydrolase
(PAF-AH, lipoprotein associated phospholipase A2).
Cardiovasc Drugs Ther, 2009, 23:73–83.
Stafforini DM, McIntyre TM, Zimmerman GA, et al. Plateletactivating
factor, a pleiotrophic mediator of physiological and
pathological processes. Crit Rev Clin Lab Sci, 2003, 40:
643–672.
Stafforini DM, Sheller JR, Blackwell TS, et al. Release of free
F2-isoprostanes from esterified phospholipids is catalyzed by
intracellular and plasma platelet-activating factor acetylhydrolases.
J Biol Chem, 2006, 281:4616–4623.
Tai HH, Ensor CM, Tong M, et al. Prostaglandin catabolizing
enzymes. Prostaglandins Other Lipid Mediat, 2002, 68–69:
483–493.
Terry MB, Gammon MD, Zhang FF, et al. Association of frequency
and duration of aspirin use and hormone receptor status
with breast cancer risk. JAMA, 2004, 291:2433–2440.
Tilley SL, Coffman TM, Koller BH. Mixed messages: Modulation
of inflammation and immune responses by prostaglandins and
thromboxanes. J Clin Invest, 2001, 108:15–23.
Toda A, Yokomizo T, Shimizu T. Leukotriene B4 receptors.
Prostaglandins Other Lipid Mediat, 2002, 68–69:575–585.
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of
action for aspirin-like drugs. Nat New Biol, 1971, 231:
232–235.
Wang M, Lee E, Song W, et al. Microsomal prostaglandin E
synthase-1 deletion suppresses oxidative stress and
angiotensin II-induced abdominal aortic aneurysm formation.
Circulation, 2008, 117:1302–1309.
Wang M, Zukas AM, Hui Y, et al. Deletion of microsomal
prostaglandin E synthase-1 augments prostacyclin and retards
atherogenesis. Proc Natl Acad Sci U S A, 2006, 103:14507–14512.
Woodward DF, Carling RW, Cornell CL, et al. The pharmacology
and therapeutic relevance of endocannabinoid derived
cyclo-oxygenase (COX)-2 products. Pharmacol Ther, 2008,
120:71–80.
Zhang Z, Vezza R, Plappert T, et al. COX-2-dependent cardiac failure
in Gh/tTG transgenic mice. Circ Res, 2003, 92:1153–1161.
Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM.
The platelet-activating factor signaling system and its regulators
in syndromes of inflammation and thrombosis. Crit Care
Med 2002, 30(suppl):S294–S301.
957
CHAPTER 33
LIPID-DERIVED AUTACOIDS: EICOSANOIDS AND PLATELET-ACTIVATING FACTOR